បច្ចេកវិទ្យាហ្សែនចែករំលែកលោតបន្ទាប់ពីសម្ព័ន្ធភាពយុទ្ធសាស្ត្រជាមួយ Qiagen

• បច្ចេកវិទ្យាហ្សែនលីមីតធីត (ផ្សារហ៊ុន NASDAQ: ទូទៅ) agreed to form a strategic alliance with ក្រុមហ៊ុន Qiagen NV (NYSE: QGEN) to establish and develop a ‘Centre of Excellence facility in Australia.

• Qiagen will support the improvement of GTG capabilities through software, hardware, consumable and technical solutions.

• Genetic Technologies CEO Simon Morriss said it was an exciting opportunity for the company.

• “We are extremely excited to be forming this alliance with the regional subsidiary of such a prestigious global partner,” he said.

• “After extensive trialing throughout 2022, we are now onboarding this capability within our labs and will see significant benefits with automation.

• “We also see this relationship unlocking the reimbursable market within Australia, as our local GP clinics progressively adopt our tests.”

• The deal will also open the door to a wide range of new commercial opportunities for Genetic with greater automation capability and increased capacity, leading to long-term revenue growth.

• Genetic Technologies said the partnership would make its geneType breast, ovarian and colorectal cancer tests the “most comprehensive offering” in the market in 2023.

• សកម្មភាពតម្លៃ: GENE shares are up 6.16% at $0.97 on the last check Wednesday.

កុំខកខានការជូនដំណឹងតាមពេលវេលាជាក់ស្តែងលើភាគហ៊ុនរបស់អ្នក – ចូលរួម ប្រូម៉ាណា ដោយ​ឥតគិតថ្លៃ! សាកល្បងឧបករណ៍ដែលនឹងជួយអ្នកឱ្យវិនិយោគកាន់តែឆ្លាតវៃ លឿនជាងមុន និងប្រសើរជាងមុន។.

អត្ថបទ​នេះ បច្ចេកវិទ្យាហ្សែនចែករំលែកលោតបន្ទាប់ពីសម្ព័ន្ធភាពយុទ្ធសាស្ត្រជាមួយ Qiagen ដើមដំបូងបានបង្ហាញខ្លួន benzinga.com

.

© ២០២០ Benzinga.com ។ Benzinga មិនផ្តល់ដំបូន្មានវិនិយោគទេ។ រក្សា​រ​សិទ្ធ​គ្រប់យ៉ាង។